Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of fezolinetant in menopausal women with vasomotor symptoms
2019-000275-16Phase 3Unknown
- Sponsor
- Astellas Pharma
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in menopause and hot flash comparing Fezolinetant with Placebo (2 arms). Primary endpoint: Long-term safety and tolerability of fezolinetant. Status: unknown.
02
Drugs
fezolinetant
03
Conditions
menopausehot flash
Beyond the preview
Go deeper on 2019-000275-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000275-16.